Technical Analysis for JNCE - Jounce Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical JNCE trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 200 DMA Resistance | Bearish | 0.00% | |
| MACD Bearish Signal Line Cross | Bearish | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Fell Below 200 DMA | Bearish | -1.99% | |
| Earnings Movers | Other | -1.99% | |
| Down 3 Days in a Row | Weakness | -1.99% | |
| Down 4 Days in a Row | Weakness | -1.99% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Fell Below Lower Bollinger Band | about 5 hours ago |
| Down 2 % | about 6 hours ago |
| Lower Bollinger Band Support | about 6 hours ago |
| Down 1% | about 8 hours ago |
| 200 DMA Resistance | about 9 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/04/2021
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It engaged in developing therapies which enable the immune system to attack tumors. The Company's lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of certain T cells found in a range of solid tumors. It also developing JTX-4014 for use in future combinations with JTX-2011, as well as for use in combination with other future product candidates. Jounce Therapeutics, Inc. is based in Cambridge, United States.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Biology Immunology Solid Tumors Immune System Natural Sciences Immunotherapy Monoclonal Antibody Monoclonal Antibodies
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Biology Immunology Solid Tumors Immune System Natural Sciences Immunotherapy Monoclonal Antibody Monoclonal Antibodies
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 14.79 |
| 52 Week Low | 4.3 |
| Average Volume | 413,930 |
| 200-Day Moving Average | 8.57 |
| 50-Day Moving Average | 10.51 |
| 20-Day Moving Average | 9.30 |
| 10-Day Moving Average | 9.28 |
| Average True Range | 0.64 |
| ADX | 11.0 |
| +DI | 18.24 |
| -DI | 28.69 |
| Chandelier Exit (Long, 3 ATRs ) | 8.93 |
| Chandelier Exit (Short, 3 ATRs ) | 10.12 |
| Upper Bollinger Band | 10.35 |
| Lower Bollinger Band | 8.25 |
| Percent B (%b) | 0.05 |
| BandWidth | 22.64 |
| MACD Line | -0.40 |
| MACD Signal Line | -0.39 |
| MACD Histogram | -0.0143 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 9.19 | ||||
| Resistance 3 (R3) | 9.25 | 9.03 | 9.05 | ||
| Resistance 2 (R2) | 9.03 | 8.82 | 9.00 | 9.00 | |
| Resistance 1 (R1) | 8.70 | 8.69 | 8.59 | 8.64 | 8.96 |
| Pivot Point | 8.48 | 8.48 | 8.43 | 8.45 | 8.48 |
| Support 1 (S1) | 8.15 | 8.27 | 8.04 | 8.09 | 7.76 |
| Support 2 (S2) | 7.93 | 8.14 | 7.90 | 7.72 | |
| Support 3 (S3) | 7.60 | 7.93 | 7.67 | ||
| Support 4 (S4) | 7.54 |
